Rothschild & Co Asset Management US’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $515K | Sell |
1,960
-50
| -2% | -$13.4K | 0.01% | 251 |
|
|
2022
Q3 | $453K | Hold |
2,010
| – | – | 0.01% | 254 |
|
|
2022
Q2 | $489K | Hold |
2,010
| – | – | 0.01% | 260 |
|
|
2022
Q1 | $486K | Sell |
2,010
-10
| -0.5% | -$2.3K | 0.01% | 262 |
|
|
2021
Q4 | $454K | Hold |
2,020
| – | – | 0.01% | 269 |
|
|
2021
Q3 | $430K | Sell |
2,020
-80
| -4% | -$18.4K | 0.01% | 268 |
|
|
2021
Q2 | $512K | Hold |
2,100
| – | – | 0.01% | 264 |
|
|
2021
Q1 | $523K | Sell |
2,100
-30
| -1% | -$7.16K | 0.01% | 268 |
|
|
2020
Q4 | $490K | Hold |
2,130
| – | – | 0.01% | 280 |
|
|
2020
Q3 | $541K | Buy |
2,130
+170
| +9% | +$42.1K | 0.01% | 290 |
|
|
2020
Q2 | $462K | Buy |
1,960
+360
| +23% | +$82.1K | 0.01% | 305 |
|
|
2020
Q1 | $324K | Hold |
1,600
| – | – | 0.01% | 319 |
|
|
2019
Q4 | $386K | Sell |
1,600
-50
| -3% | -$11K | ﹤0.01% | 337 |
|
|
2019
Q3 | $319K | Sell |
1,650
-50
| -3% | -$9.6K | ﹤0.01% | 342 |
|
|
2019
Q2 | $313K | Hold |
1,700
| – | – | ﹤0.01% | 345 |
|
|
2019
Q1 | $323K | Sell |
1,700
-2,206
| -56% | -$421K | ﹤0.01% | 357 |
|
|
2018
Q4 | $760K | Sell |
3,906
-8
| -0.2% | -$1.56K | 0.01% | 360 |
|
|
2018
Q3 | $811K | Sell |
3,914
-101
| -3% | -$19.9K | 0.01% | 358 |
|
|
2018
Q2 | $741K | Sell |
4,015
-698
| -15% | -$123K | 0.01% | 364 |
|
|
2018
Q1 | $803K | Sell |
4,713
-139,904
| -97% | -$25.7M | 0.01% | 344 |
|
|
2017
Q4 | $25.1M | Sell |
144,617
-1,665
| -1% | -$295K | 0.27% | 161 |
|
|
2017
Q3 | $27.3M | Sell |
146,282
-159,998
| -52% | -$28.3M | 0.3% | 143 |
|
|
2017
Q2 | $52.8M | Sell |
306,280
-7,692
| -2% | -$1.25M | 0.6% | 42 |
|
|
2017
Q1 | $51.5M | Sell |
313,972
-1,083
| -0.3% | -$180K | 0.59% | 39 |
|
|
2016
Q4 | $46.1M | Buy |
315,055
+101,645
| +48% | +$15.3M | 0.59% | 36 |
|
|
2016
Q3 | $35.6M | Sell |
213,410
-12,058
| -5% | -$2.04M | 0.61% | 27 |
|
|
2016
Q2 | $34.3M | Sell |
225,468
-20,044
| -8% | -$3.12M | 0.62% | 31 |
|
|
2016
Q1 | $36.8M | Sell |
245,512
-73,645
| -23% | -$10.9M | 0.69% | 36 |
|
|
2015
Q4 | $51.8M | Buy |
319,157
+61,766
| +24% | +$9.71M | 0.94% | 14 |
|
|
2015
Q3 | $35.6M | Buy |
257,391
+7,375
| +3% | +$1.16M | 0.7% | 32 |
|
|
2015
Q2 | $38.4M | Sell |
250,016
-29,211
| -10% | -$4.68M | 0.71% | 37 |
|
|
2015
Q1 | $44.6M | Sell |
279,227
-28,006
| -9% | -$4.41M | 0.85% | 19 |
|
|
2014
Q4 | $49.4M | Sell |
307,233
-30,332
| -9% | -$4.73M | 0.99% | 16 |
|
|
2014
Q3 | $47.4M | Buy |
337,565
+167,539
| +99% | +$21.9M | 1.01% | 19 |
|
|
2014
Q2 | $20.1M | Buy |
170,026
+6,505
| +4% | +$753K | 0.41% | 65 |
|
|
2014
Q1 | $20.2M | Buy |
163,521
+157,235
| +2,501% | +$19.1M | 0.45% | 61 |
|
|
2013
Q4 | $717K | Sell |
6,286
-60
| -0.9% | -$6.83K | 0.02% | 357 |
|
|
2013
Q3 | $710K | Sell |
6,346
-110
| -2% | -$11.9K | 0.02% | 351 |
|
|
2013
Q2 | $637K | Buy |
+6,456
| New | +$670K | 0.01% | 354 |
|
Other funds holding AMGN
AWA
Rothschild & Co Asset Management US's AMGN Position: Q4 2022 in Review
Rothschild & Co Asset Management US reduced its Amgen (AMGN) stake by 2.5% in Q4 2022, selling an estimated $13.4K and leaving 1,960 shares worth $515K. The position accounts for 0.01% of the portfolio, ranked #251.
Rothschild & Co Asset Management US first reported a position in AMGN in Q2 2013 and has held it in 39 quarters since. The position peaked at $52.8M in Q2 2017. 2,502 funds tracked by Wall St. Rank hold AMGN as of Q4 2022.
- Rothschild & Co Asset Management US held 1,960 shares of Amgen worth $515K as of Q4 2022.
- Rothschild & Co Asset Management US sold 50 Amgen shares in Q4 2022, an estimated $13.4K.
- Amgen made up 0.01% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #251 holding.
- Rothschild & Co Asset Management US first reported a position in Amgen in Q2 2013 and has held it in 39 quarters since.
- Rothschild & Co Asset Management US's Amgen position peaked at $52.8M in Q2 2017.
- 2,502 funds tracked by Wall St. Rank held Amgen as of Q4 2022.
Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.